Artelo Biosciences, Inc. (ARTL)
NASDAQ: ARTL · Real-Time Price · USD
1.530
-0.100 (-6.13%)
At close: Feb 3, 2026, 4:00 PM EST
1.570
+0.040 (2.61%)
After-hours: Feb 3, 2026, 4:45 PM EST
Artelo Biosciences Employees
Artelo Biosciences had 5 employees as of June 30, 2025. The number of employees did not change compared to the same quarter last year.
Employees
5
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,498,200
Market Cap
3.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 5 | 0 | - |
| Mar 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 6 | 0 | - |
| Sep 30, 2024 | 5 | 0 | - |
| Jun 30, 2024 | 5 | 0 | - |
| Mar 31, 2024 | 5 | 0 | - |
| Dec 31, 2023 | 6 | -1 | -14.29% |
| Sep 30, 2023 | 5 | 1 | 25.00% |
| Jun 30, 2023 | 5 | 1 | 25.00% |
| Mar 31, 2023 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 7 | 2 | 40.00% |
| Sep 30, 2022 | 4 | -1 | -20.00% |
| Jun 30, 2022 | 4 | - | - |
| Mar 31, 2022 | 4 | - | - |
| Dec 31, 2021 | 5 | 2 | 66.67% |
| Nov 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 29, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Nov 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| May 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Feb 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Jaguar Health | 49 |
| Scinai Immunotherapeutics | 31 |
| Lyra Therapeutics | 30 |
| Galmed Pharmaceuticals | 6 |
| CNS Pharmaceuticals | 5 |
| Oragenics | 5 |
| XORTX Therapeutics | 3 |
| Matinas BioPharma Holdings | 3 |
ARTL News
- 6 weeks ago - Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate - GlobeNewsWire
- 2 months ago - Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer - GlobeNewsWire
- 3 months ago - Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer - GlobeNewsWire
- 3 months ago - Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit - GlobeNewsWire
- 4 months ago - Artelo Biosciences Announces Closing of $2.0 Million Public Offering - GlobeNewsWire
- 4 months ago - Artelo Biosciences Announces Pricing of $2.0 Million Public Offering - GlobeNewsWire
- 4 months ago - Artelo Biosciences Announces Proposed Underwritten Public Offering - GlobeNewsWire